Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor

Koji Kawai, Shiro Hinotsu, Takehiro Oikawa, Noritoshi Sekido, Kazunori Hattori, Naoto Miyanaga, Yuichi Hasegawa, Hiroshi Kojima, Toru Shimazui, Hideyuki Akaza

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Incidence of testicular cancer is low in Japan. Recent investigations showed that the outcome of metastatic testicular cancer is associated with the experience of the treatment institution. Objectives of the present investigation are to evaluate outcome of a single institution in Japan, and to identify prognostic factors for testicular cancer. Methods: We retrospectively analysed the outcome of 74 patients with metastatic testicular cancer who were treated at Tsukuba University Hospital (TUH) between January 1981 and January 2003. Forty-five patients (61%) were referred to the TUH for the treatment of metastatic disease. The progression-free survival (PFS) rates according to the International Germ Cell Cancer (IGCC) classification and the Indiana University classification were used to evaluate the treatment outcome. Results: The median follow-up period of all patients was 87 months (range, 13-260 months). Forty patients (54%) were classified as having good prognosis, 20 (27%) intermediate, and 14 (19%) poor. The overall 5-and 10-year PFS was 79 and 74%, respectively. The 5-year PFS with good, intermediate and poor prognosis was 90, 70 and 64%, respectively. There was a significant difference between the three groups (P = 0.02), but the survival of the intermediate-prognosis group was not statistically different from that of the poor-prognosis group. The Indiana University classification failed to discriminate the prognoses of moderate and advanced disease, but proved to be an independent prognostic factor for progressionfree survival in intermediate-and poor-prognosis patients (P = 0.025, hazard ratio = 5.39). Conclusions: Our treatment outcome is not different from that of the institutions participating in the International Germ Cell Cancer Consensus Group (IGCCCG).

Original languageEnglish
Pages (from-to)723-730
Number of pages8
JournalJapanese Journal of Clinical Oncology
Volume36
Issue number11
DOIs
Publication statusPublished - Sep 2006
Externally publishedYes

Fingerprint

Germ Cell and Embryonal Neoplasms
Testicular Neoplasms
Japan
Incidence
Disease-Free Survival
Survival
Survival Rate
Therapeutics

Keywords

  • Chemotherapy
  • IGCCCG classification
  • Indiana University classification
  • Testicular cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor. / Kawai, Koji; Hinotsu, Shiro; Oikawa, Takehiro; Sekido, Noritoshi; Hattori, Kazunori; Miyanaga, Naoto; Hasegawa, Yuichi; Kojima, Hiroshi; Shimazui, Toru; Akaza, Hideyuki.

In: Japanese Journal of Clinical Oncology, Vol. 36, No. 11, 09.2006, p. 723-730.

Research output: Contribution to journalArticle

Kawai, K, Hinotsu, S, Oikawa, T, Sekido, N, Hattori, K, Miyanaga, N, Hasegawa, Y, Kojima, H, Shimazui, T & Akaza, H 2006, 'Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor', Japanese Journal of Clinical Oncology, vol. 36, no. 11, pp. 723-730. https://doi.org/10.1093/jjco/hyl102
Kawai, Koji ; Hinotsu, Shiro ; Oikawa, Takehiro ; Sekido, Noritoshi ; Hattori, Kazunori ; Miyanaga, Naoto ; Hasegawa, Yuichi ; Kojima, Hiroshi ; Shimazui, Toru ; Akaza, Hideyuki. / Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor. In: Japanese Journal of Clinical Oncology. 2006 ; Vol. 36, No. 11. pp. 723-730.
@article{96edcdfd198d4f949c5362454b4aff3e,
title = "Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor",
abstract = "Background: Incidence of testicular cancer is low in Japan. Recent investigations showed that the outcome of metastatic testicular cancer is associated with the experience of the treatment institution. Objectives of the present investigation are to evaluate outcome of a single institution in Japan, and to identify prognostic factors for testicular cancer. Methods: We retrospectively analysed the outcome of 74 patients with metastatic testicular cancer who were treated at Tsukuba University Hospital (TUH) between January 1981 and January 2003. Forty-five patients (61{\%}) were referred to the TUH for the treatment of metastatic disease. The progression-free survival (PFS) rates according to the International Germ Cell Cancer (IGCC) classification and the Indiana University classification were used to evaluate the treatment outcome. Results: The median follow-up period of all patients was 87 months (range, 13-260 months). Forty patients (54{\%}) were classified as having good prognosis, 20 (27{\%}) intermediate, and 14 (19{\%}) poor. The overall 5-and 10-year PFS was 79 and 74{\%}, respectively. The 5-year PFS with good, intermediate and poor prognosis was 90, 70 and 64{\%}, respectively. There was a significant difference between the three groups (P = 0.02), but the survival of the intermediate-prognosis group was not statistically different from that of the poor-prognosis group. The Indiana University classification failed to discriminate the prognoses of moderate and advanced disease, but proved to be an independent prognostic factor for progressionfree survival in intermediate-and poor-prognosis patients (P = 0.025, hazard ratio = 5.39). Conclusions: Our treatment outcome is not different from that of the institutions participating in the International Germ Cell Cancer Consensus Group (IGCCCG).",
keywords = "Chemotherapy, IGCCCG classification, Indiana University classification, Testicular cancer",
author = "Koji Kawai and Shiro Hinotsu and Takehiro Oikawa and Noritoshi Sekido and Kazunori Hattori and Naoto Miyanaga and Yuichi Hasegawa and Hiroshi Kojima and Toru Shimazui and Hideyuki Akaza",
year = "2006",
month = "9",
doi = "10.1093/jjco/hyl102",
language = "English",
volume = "36",
pages = "723--730",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor

AU - Kawai, Koji

AU - Hinotsu, Shiro

AU - Oikawa, Takehiro

AU - Sekido, Noritoshi

AU - Hattori, Kazunori

AU - Miyanaga, Naoto

AU - Hasegawa, Yuichi

AU - Kojima, Hiroshi

AU - Shimazui, Toru

AU - Akaza, Hideyuki

PY - 2006/9

Y1 - 2006/9

N2 - Background: Incidence of testicular cancer is low in Japan. Recent investigations showed that the outcome of metastatic testicular cancer is associated with the experience of the treatment institution. Objectives of the present investigation are to evaluate outcome of a single institution in Japan, and to identify prognostic factors for testicular cancer. Methods: We retrospectively analysed the outcome of 74 patients with metastatic testicular cancer who were treated at Tsukuba University Hospital (TUH) between January 1981 and January 2003. Forty-five patients (61%) were referred to the TUH for the treatment of metastatic disease. The progression-free survival (PFS) rates according to the International Germ Cell Cancer (IGCC) classification and the Indiana University classification were used to evaluate the treatment outcome. Results: The median follow-up period of all patients was 87 months (range, 13-260 months). Forty patients (54%) were classified as having good prognosis, 20 (27%) intermediate, and 14 (19%) poor. The overall 5-and 10-year PFS was 79 and 74%, respectively. The 5-year PFS with good, intermediate and poor prognosis was 90, 70 and 64%, respectively. There was a significant difference between the three groups (P = 0.02), but the survival of the intermediate-prognosis group was not statistically different from that of the poor-prognosis group. The Indiana University classification failed to discriminate the prognoses of moderate and advanced disease, but proved to be an independent prognostic factor for progressionfree survival in intermediate-and poor-prognosis patients (P = 0.025, hazard ratio = 5.39). Conclusions: Our treatment outcome is not different from that of the institutions participating in the International Germ Cell Cancer Consensus Group (IGCCCG).

AB - Background: Incidence of testicular cancer is low in Japan. Recent investigations showed that the outcome of metastatic testicular cancer is associated with the experience of the treatment institution. Objectives of the present investigation are to evaluate outcome of a single institution in Japan, and to identify prognostic factors for testicular cancer. Methods: We retrospectively analysed the outcome of 74 patients with metastatic testicular cancer who were treated at Tsukuba University Hospital (TUH) between January 1981 and January 2003. Forty-five patients (61%) were referred to the TUH for the treatment of metastatic disease. The progression-free survival (PFS) rates according to the International Germ Cell Cancer (IGCC) classification and the Indiana University classification were used to evaluate the treatment outcome. Results: The median follow-up period of all patients was 87 months (range, 13-260 months). Forty patients (54%) were classified as having good prognosis, 20 (27%) intermediate, and 14 (19%) poor. The overall 5-and 10-year PFS was 79 and 74%, respectively. The 5-year PFS with good, intermediate and poor prognosis was 90, 70 and 64%, respectively. There was a significant difference between the three groups (P = 0.02), but the survival of the intermediate-prognosis group was not statistically different from that of the poor-prognosis group. The Indiana University classification failed to discriminate the prognoses of moderate and advanced disease, but proved to be an independent prognostic factor for progressionfree survival in intermediate-and poor-prognosis patients (P = 0.025, hazard ratio = 5.39). Conclusions: Our treatment outcome is not different from that of the institutions participating in the International Germ Cell Cancer Consensus Group (IGCCCG).

KW - Chemotherapy

KW - IGCCCG classification

KW - Indiana University classification

KW - Testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=39049178211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049178211&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyl102

DO - 10.1093/jjco/hyl102

M3 - Article

VL - 36

SP - 723

EP - 730

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 11

ER -